

## Appendix 4E

### Preliminary Final Report

#### 1. Company details

Name of entity

**Pro Medicus Limited**

ABN or equivalent  
company reference

**25 006 194 752**

Financial year ended  
(‘current period’)

**30 June 2012**

Financial year ended  
(‘previous period’)

**30 June 2011**

#### 2. Results for announcement to the market

ASX Listing Rules Ref		2011 A\$'000
2.1	<b>Revenue from continuing operations</b>  <b>Revenue from discontinued operations</b>  <b>Total Revenue</b>  % change up/(down) of revenue from ordinary activities from the previous corresponding period.	11,379  3,013  14,326  Up 2.56%
2.2	<b>Profit after tax attributable to members</b>  % change up/(down) of Profit/(Loss) from ordinary activities after tax attributable to members from the previous corresponding period.	1,791  Up 256.1%
2.3	<b>Net Profit for the period attributable to members</b>  % change up/(down) of Net Profit/(Loss) for the period attributable to members from the previous corresponding period.	1,791  Up 256.1%

2.4	Dividends (distributions)	Amount per security	Fully Franked amount per security
	Franked dividend amount per security		
	Final Dividend	1.0 cents	1.0 cents
	Interim dividend	0.5 cents	0.5 cents
2.5	<b>Record date for Final dividends</b>	14 September 2012	
	Payment date for Final dividends	5 October 2012	

<p><b>2.6</b></p>	<p><b>Australia</b> The group employs 28 people in Australia who undertake research and development of Pro Medicus products as well as sales and service/support functions.</p> <p>The group's Australian revenue declined over the period by 6.75% due to delays in commercialisation of the company's new RIS technology platform to market.</p> <p>Promedicus.net, the company's e-health offering, continued to hold its strong market position recording revenue of \$1.75 million despite increasing competition.</p> <p><b>North America</b> The group employs 10 people in North America to fulfil the sales marketing and professional services roles. Revenue from North America declined by 3.8% compared to the previous year. The company made a number of changes in the group's US management and operations during the past year including a significant decrease in overall running costs. The company believes these changes will have a positive impact on the performance of the North American division.</p> <p><b>Europe</b> Pro Medicus established a presence in Europe with the acquisition of Visage Imaging GmbH in late January 2009. The group has 41 employees in its Berlin office who undertake research and development of Visage Imaging products worldwide as well as sales, marketing and service/support functions for the group's European operations. Revenue from our European operations increased by 24.6% compared to the previous year.</p> <p><b>Financials</b> Full year revenue from continuing operations, rose from \$11.18 million to \$11.38 million, an increase of 1.8% with net margin as defined by profit before tax to revenue from operating activities rising from (9.0%) to 9.0%.</p> <p>Profit after tax for the period was \$1.79 million an increase of 256.1% from the previous year reflecting higher margins and decreased ongoing costs.</p> <p><b>Shareholder Returns</b> The directors are confident that the holdings of reserve cash is sufficient to underpin the development and expansion needs of the company as the business looks to increase its penetration of existing markets and new product development.</p>
<p><b>3.</b></p>	<p><b>Statement of Comprehensive Income</b> Please refer to the Statement of Comprehensive Income in the attached Financial Statements.</p>
<p><b>4.</b></p>	<p><b>Statement of Financial Position</b> Please refer to the Statement of Financial Position in the attached Financial Statements.</p>
<p><b>5.</b></p>	<p><b>Statement of cash flows</b> Please refer to the Statement of cash flows in the attached Financial Statements.</p>

6.	<p><b>Details of Dividends</b></p> <table border="0" style="width: 100%;"> <thead> <tr> <th style="width: 70%;"></th> <th style="text-align: right; width: 15%;">2012 \$'000</th> <th style="text-align: right; width: 15%;">2011 \$'000</th> </tr> </thead> <tbody> <tr> <td><b>Final Dividend</b></td> <td></td> <td></td> </tr> <tr> <td>A Final Dividend of 1.0 cents (2011: Nil) per share fully franked will be paid on 5<sup>th</sup> October 2012.</td> <td style="text-align: right;">1,002</td> <td style="text-align: right;">Nil</td> </tr> <tr> <td><b>Current Year Interim</b></td> <td></td> <td></td> </tr> <tr> <td>An interim dividend of 0.50 cents (2011: Nil) per share fully franked was paid on 21 March 2012.</td> <td style="text-align: right;">\$501</td> <td style="text-align: right;">-</td> </tr> <tr> <td colspan="3">No foreign sourced dividend or distribution is included in either the interim or final dividends.</td> </tr> </tbody> </table>		2012 \$'000	2011 \$'000	<b>Final Dividend</b>			A Final Dividend of 1.0 cents (2011: Nil) per share fully franked will be paid on 5 <sup>th</sup> October 2012.	1,002	Nil	<b>Current Year Interim</b>			An interim dividend of 0.50 cents (2011: Nil) per share fully franked was paid on 21 March 2012.	\$501	-	No foreign sourced dividend or distribution is included in either the interim or final dividends.		
	2012 \$'000	2011 \$'000																	
<b>Final Dividend</b>																			
A Final Dividend of 1.0 cents (2011: Nil) per share fully franked will be paid on 5 <sup>th</sup> October 2012.	1,002	Nil																	
<b>Current Year Interim</b>																			
An interim dividend of 0.50 cents (2011: Nil) per share fully franked was paid on 21 March 2012.	\$501	-																	
No foreign sourced dividend or distribution is included in either the interim or final dividends.																			
7.	<p><b>Dividend or Distribution reinvestment plans</b></p> <p>There are no dividend or distribution reinvestment plans in operation.</p>																		
8.	<p><b>Statement of Retained Earnings</b></p> <p>Please refer to Statement of Changes in Equity in the attached Financial Statements.</p>																		
9.	<table border="0" style="width: 100%;"> <thead> <tr> <th style="width: 70%;"></th> <th style="text-align: right; width: 15%;">2012</th> <th style="text-align: right; width: 15%;">2011</th> </tr> </thead> <tbody> <tr> <td><b>Net Tangible Assets per security</b></td> <td></td> <td></td> </tr> <tr> <td>Net Tangible Assets per security</td> <td style="text-align: right;"><b>\$0.05</b></td> <td style="text-align: right;">\$0.02</td> </tr> </tbody> </table>		2012	2011	<b>Net Tangible Assets per security</b>			Net Tangible Assets per security	<b>\$0.05</b>	\$0.02									
	2012	2011																	
<b>Net Tangible Assets per security</b>																			
Net Tangible Assets per security	<b>\$0.05</b>	\$0.02																	
10.	<p><b>Details of entities over which control has been gained or lost during the period</b></p> <p>There are no entities over which control has been gained or lost during the period</p>																		
11.	<p><b>Associates and joint venture entities</b></p> <p>There are no associates or joint venture entities</p>																		
12.	<p><b>Other significant information needed by an investor to make an informed assessment of the entity's financial performance and financial position.</b></p> <p>Please refer to section 2.6</p>																		
13.	<p><b>Foreign Entity accounting standards</b></p> <p>Australian Accounting Standards &amp; International Financial Reporting Standards</p>																		

14.	<p><b>Commentary on results for the period.</b> <b>The earnings per security and the nature of any dilution aspects.</b> Please refer to Note 9 of the attached Financial Statements.</p> <p><b>Returns to shareholders including distributions and buy backs.</b> Please refer to Note 10 of the attached Financial Statements.</p> <p><b>Significant features of operating performance.</b> Please refer to section 2.6.</p> <p><b>The results of segments that are significant to an understanding of the business.</b> Please refer to Note 5 of the attached Financial Statements.</p> <p><b>Discussion of trends in performance.</b> Please refer to section 2.6.</p>
15.	<p><b>Audit Statement</b></p> <p>This report is based on accounts to which one of the following applies. (Tick one)</p> <p><input checked="" type="checkbox"/> The +accounts have been audited.      <input type="checkbox"/> The +accounts have been subject to review.</p> <p><input type="checkbox"/> The +accounts are in the process of being audited.      <input type="checkbox"/> The +accounts have <i>not</i> yet been audited or reviewed.</p>

Sign here:

Date: 24 August 2012



Print name: Sam Hupert  
Chief Executive Officer